Table 1 Characteristics of the nine studies included
Age | Male | Study country | Study design | Sample size | Poor neurologic outcome | Cut-off value (pg/ml) | OHCA | TTM | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
24 h | 48 h | 72 h | |||||||||
Adler 2021 [15] | 64 ± 12 | 83% | Germany | Retrospective | 53 | 43.4% | 241.7 | 508.6 | NA | 100% | 100% |
Huesgen 2021 [16] | 60 | 68% | America | Prospective | 22 | 54.5% | 2787 | 5237 | 16,859 | 100% | 72.7% |
Hunziker 2021 [17] | 63 ± 15 | 71% | Switzerland | Prospective | 164 | 59.8% | 50 | NA | NA | 100% | 66.5% |
Moseby–Knappe 2021 [18] | 65 | 81% | Sweden | Retrospective | 692 | 56.5% | 55 | 55 | 55 | 100% | 50.1% |
Pouplet 2022 [19] | 62 | 82% | France | Retrospective | 49 | 46.9% | NA | 500 | NA | 91.8% | NA |
Rana 2013 [20] | 63 | 74% | Germany | Prospective | 61 | 41.9% | 323 | 405 | 309 | 100% | NA |
Wihersaari 2021 [21] | 62 | 82% | Finland and Denmark | Retrospective | 112 | 34.8% | 127 | 263 | 344 | 100% | 100% |
Wihersaari 2022 [22] | 63 | 84% | Finland | Retrospective | 197 | 48.4% | 232 | NA | NA | 100% | 77.4% |
Wurm 2021 [23] | 56 | 76% | Austria | Retrospective | 70 | 70.0% | NA | NA | NA | 100% | 100% |